

Acquisition of AboundBio & CellPoint propels Galapagos into next-generation cell therapy

Combatting cancer with potentially transformational medicines

We believe that real differentiation and access to therapy could come from a disruptive CAR-T manufacturing model at point-of-care, close to patients, combined with innovative science and expert teams.

Potential to disrupt the CAR-T manufacturing model

CellPoint brings a clinical CAR-T pipeline and a novel point-of-care solution that offers the potential for efficient, 7-day time to treatment and avoids complex logistics, thereby addressing important limitations of current CAR-T treatments.

Clinical validation of point-of-care CAR-T manufacturing model

Two Phase 1/2a studies with CD19 CAR-T product candidate ongoing in relapsed/refractory Non-Hodgkin's Lymphoma (rrNHL) and Chronic Lymphocytic Leukemia (rrCLL), with topline results expected in H1 2023, providing the opportunity for a rapid clinical validation of decentralized supply model.

Access to cutting edge science for next generation CAR-Ts

AboundBio's cutting-edge fully human antibody-based platform provides access to a research engine for next generation CAR-T therapies that have the potential to deliver deeper and durable clinical responses, as well as biospecific antibodies and antibody drug conjugates (ADCs)

Deploying Galapagos' end-to-end capabilities and financial resources

Positions Galapagos in next-generation cancer therapy market and significantly broadens portfolio and capabilities.

Galapagos' transformation to strengthen our R&D pipeline and capabilities has started

The companies' joint goal is to bring three differentiated, next-generation CAR-T candidates in the clinic over the next three years.

A first key step in our strategic transformation to accelerate and diversify our pipeline with the aim to create short- and long-term value through focused external growth.

In parallel, we will further map out the next strategic steps and explore additional corporate development opportunities to further leverage our internal capabilities and renew our portfolio. We expect to communicate further details later this year.



Transaction highlights



€125m

Acquisition of CellPoint for an amount of €125 million, with milestone payments up to €100 million

\$14m

Acquisition of AboundBio for an amount of \$14 million



With the transactions announced today, we position ourselves as a potential innovator in CAR-T, while building a strong foundation from which we can drive continued innovation for patients with advanced cancers who are in need of new treatment options. This is a first key step in our strategic transformation to accelerate and diversify our pipeline with the aim to create short- and long-term value through focused external growth. We continue to explore additional business development opportunities to further leverage our internal capabilities and renew our portfolio, and we expect to communicate a detailed update on our corporate strategy and portfolio later this year. With the support of our collaboration partner Gilead, we warmly welcome the CellPoint and AboundBio teams to Galapagos, and together we look forward to potentially bringing transformational medicines to patients worldwide.

Paul Stoffels, MD, CEO of Galapagos



Galapagos

Aboundbio

CellPoint